Alyeska Investment Group
CTIC

Alyeska Investment Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Alyeska Investment Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-196,752
Closed -$767K – 613
2018
Q1 		$767K Buy
+196,752
New +$692K 0.01% 406
2017
Q3 		– Sell
-466,529
Closed -$1.54M – 609
2017
Q2 		$1.54M Buy
+466,529
New +$1.82M 0.01% 369
2016
Q3 		– Sell
-78,949
Closed -$268K – 592
2016
Q2 		$268K Buy
78,949
+1,602
+2% +$7.35K ﹤0.01% 413
2016
Q1 		$411K Buy
77,347
+2,347
+3% +$18.8K ﹤0.01% 367
2015
Q4 		$923K Buy
+75,000
New +$1M 0.01% 342

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $408M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $581M AUM 108.65% 1-Year Est. Return